Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes
Diabetes, Obesity and Metabolism · 2024-09 · 26 (9) · 3897-3905
DOI: 10.1111/dom.15736 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024-07. Verfasst von Daniel R Quast und 10 weiteren Autor:innen. Beteiligte Einrichtung: Adelaide Medical School and Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health, The University of Adelaide, Adelai…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Cross-Over Studies, Blood Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Royal Adelaide Hospital Research Committee Clinical Project Grant.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To perform a direct, double‐blind, randomised, crossover comparison of subcutaneous and intravenous glucagon‐like peptide‐1 (GLP‐1) in hyperglycaemic subjects with type 2 diabetes naïve to GLP‐1‐based therapy. Materials and Methods Ten fasted, hyperglycaemic subjects (1 female, age 63 ± 10 years [mean ± SD], glycated haemoglobin 73.5 ± 22.0 mmol/mol [8.9% ± 2.0%], both mean ± SD) received subcutaneous GLP‐1 and intravenous saline, or intravenous GLP‐1 and subcutaneous saline. Infusion rates were doubled every 120 min (1.2, 2.4, 4.8 and 9.6 pmol·kg −1 ·min −1 for subcutaneous, and 0.3, 0.6, 1.2 and 2.4 pmol·kg −1 ·min −1 for intravenous). Plasma glucose, total and intact GLP‐1, insulin, C‐peptide, glucagon and gastrointestinal symptoms were evaluated over 8 h. The results are presented as mean ± SEM.
Results
Plasma glucose decreased more with intravenous (by ~8.0 mmol/L [144 mg/dL]) than subcutaneous GLP‐1 (by ~5.6 mmol/L [100 mg/dL]; p < 0.001). Plasma GLP‐1 increased dose‐dependently, but more with intravenous than subcutaneous for both total (∆ max 154.2 ± 3.9 pmol/L vs. 85.1 ± 3.8 pmol/L; p < 0.001), and intact GLP‐1 (∆ max 44.2 ± 2.2 pmol/L vs. 12.8 ± 2.2 pmol/L; p < 0.001). Total and intact GLP‐1 clearance was higher for subcutaneous than intravenous GLP‐1 ( p < 0.001 and p = 0.002, respectively). The increase in insulin secretion was greater, and glucagon was suppressed more with intravenous GLP‐1 ( p < 0.05 each). Gastrointestinal symptoms did not differ ( p > 0.05 each).
Conclusions
Subcutaneous GLP‐1 administration is much less efficient than intravenous GLP‐1 in lowering fasting plasma glucose, with less stimulation of insulin and suppression of glucagon, and much less bioavailability, even at fourfold higher infusion rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adelaide Medical School and Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia.
- Diabetes, Endocrinology and Metabolism Section, Department of Internal Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
- Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
- Department of Internal Medicine, Augusta-Hospital, Bochum, Germany.
- Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia.
ORCID-Profile: Daniel R Quast, Karen L Jones, Juris J Meier, Tongzhi Wu, Christopher K Rayner, Michael A Nauck
Förderung
- National Health and Medical Research Council
- Royal Adelaide Hospital Research Committee Clinical Project Grant
Zitieren
APA
Quast, D. R., Lancaster, D., Xie, C., Bound, M. J., Grivell, J., Jones, K. L., Horowitz, M., Meier, J. J., Wu, T., Rayner, C. K., & Nauck, M. A. (2024). Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 26(9), 3897-3905. https://doi.org/10.1111/dom.15736
Vancouver
Quast DR, Lancaster D, Xie C, Bound MJ, Grivell J, Jones KL, et al. Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes, Obesity and Metabolism. 2024;26(9):3897-3905. doi:10.1111/dom.15736
BibTeX
@article{Quast2024,
author = {Quast, Daniel R and Lancaster, Dara and Xie, Cong and Bound, Michelle J and Grivell, Jacqueline and Jones, Karen L and Horowitz, Michael and Meier, Juris J and Wu, Tongzhi and Rayner, Christopher K and Nauck, Michael A},
title = {Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {9},
pages = {3897--3905},
doi = {10.1111/dom.15736}
}
EUVIMED